Recent advances in immune checkpoint inhibitors(ICIs)have transformed cancer therapy, particularly in non‒small cell lung cancer. However, monotherapy achieves limited efficacy due to resistance and an immunosuppressive tumor microenvironment. Rational combin... ...

请注册登录后继续浏览